LYEL
Lyell Immunopharma Inc
9.10$
-2.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +148.2% | -65.7% | +116.1% | +5.8% | +7.5% | +4.8% | +2.4% | -80.4% | +6,363.1% | -100.0% | +1,612,766.7% | -99.9% | -58.5% | -7.4% | -48.0% | -76.9% | +333.3% | +161.5% | -67.6% | -36.4% | +14.3% | +87.5% | -60.0% | -66.7% | +100.0% | – | |
| – | – | – | – | – | – | – | – | -0.4% | -6.1% | +11.8% | +10.1% | +9.5% | -9.7% | +12.4% | -0.9% | -0.7% | -2.4% | – | – | – | – | – | – | -2.7% | – | – | |
| – | +148.2% | -65.7% | +116.1% | -123.9% | – | +4.8% | -142.4% | – | – | -113.0% | – | -111.3% | – | – | – | – | +333.3% | +161.5% | -67.6% | -36.4% | +14.3% | +87.5% | -60.0% | -38,933.3% | – | – | |
| – | +281.0% | -74.8% | +43.2% | -18.6% | +62.6% | -32.3% | -51.3% | +114.8% | +17.4% | -5.6% | -8.2% | +20.2% | +5.3% | -5.5% | +4.1% | +3.7% | -6.7% | -1.9% | +23.2% | -10.7% | -19.8% | -19.2% | +85.3% | -29.9% | +8.0% | – | |
| – | +7.7% | +41.9% | +9.6% | +13.2% | +13.6% | +11.1% | +50.1% | +8.0% | -11.5% | -14.3% | -99.9% | +73,070.6% | -1.3% | -18.5% | -15.1% | +2.5% | -9.2% | -4.0% | +23.4% | -3.3% | -30.3% | +9.2% | -0.7% | -10.0% | +0.2% | – | |
| – | +208.5% | -64.1% | +10.3% | +8.5% | +43.9% | -20.5% | -9.1% | +42.6% | +2.6% | -9.4% | -4.4% | -0.5% | +3.1% | -9.5% | -1.3% | +1.4% | -7.3% | -1.9% | +298.0% | -71.5% | -17.8% | -21.0% | +64.5% | -28.5% | +8.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -19.6% | -41.7% | -43.3% | -43.0% | -38.4% | +23.9% | +19.6% | +22.9% | +139.8% | +136.4% | +59.9% | +1,724.2% | -92.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -164.1% | – | -103.6% | – | – | -0.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.